| 6.5 0.09 (1.4%) | 12-08 15:43 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 9.16 | 1-year : | 10.21 |
| Resists | First : | 7.84 | Second : | 8.74 |
| Pivot price | 6.82  |
|||
| Supports | First : | 6.38 | Second : | 5.31 |
| MAs | MA(5) : | 6.58 |
MA(20) : | 7.08 |
| MA(100) : | 6.92 |
MA(250) : | 10.31 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 11.9  |
D(3) : | 10.1 |
| RSI | RSI(14): 39.7 |
|||
| 52-week | High : | 20.47 | Low : | 4.75 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ PRPO ] has closed above bottom band by 14.4%. Bollinger Bands are 42.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 6.59 - 6.63 | 6.63 - 6.67 |
| Low: | 6.3 - 6.34 | 6.34 - 6.38 |
| Close: | 6.42 - 6.49 | 6.49 - 6.57 |
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.
Sat, 18 Nov 2023
Breakeven On The Horizon For Precipio, Inc. (NASDAQ:PRPO) - Simply Wall St
Thu, 16 Nov 2023
Precipio set to reach profitability in 2024 with strong growth forecast By Investing.com - Investing.com
Thu, 16 Nov 2023
When Will Precipio, Inc. (NASDAQ:PRPO) Breakeven? - Yahoo Finance
Fri, 22 Sep 2023
Precipio (NASDAQ: PRPO) to jump 2,000% at the open - nominal price change, technical - Dhaka Tribune
Sun, 13 Aug 2023
Precipio, Inc.'s (NASDAQ:PRPO) Shares Not Telling The Full Story - Yahoo Finance
Tue, 08 Jun 2021
Can Penny Stocks Make You Rich? Check These 4 Small-Caps Out - Penny Stocks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Diagnostics & Research
|
|
| Shares Out | 1 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 14 (K) |
| Shares Short P.Month | 21 (K) |
| EPS | -7.47 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 9.36 |
| Profit Margin | -68.4 % |
| Operating Margin | -32.1 % |
| Return on Assets (ttm) | -26.7 % |
| Return on Equity (ttm) | -58 % |
| Qtrly Rev. Growth | 104 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 9.33 |
| EBITDA (p.s.) | -5.48 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -5 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -0.88 |
| PEG Ratio | -0.1 |
| Price to Book value | 0.69 |
| Price to Sales | 0.69 |
| Price to Cash Flow | -1.79 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|